Acalabrutinib (Calquence, AstraZeneca) is a covalent, second-generation BTK inhibitor. 

When is Acalabrutinib Used for CLL?

Acalabrutinib is indicated for the treatment of people with CLL.  It can be used for newly diagnosed patients and those who have received prior therapy. 

How Does Acalabrutinib Work?

Acalabrutinib works by permanently (covalent) binding to the cysteine residue (Cys481) on the BTK protein, interfering with the survival and growth of CLL cells. 

How is Acalabrutinib Administered?

Acalabrutinib is taken as a tablet by mouth. The standard dosage for acalabrutinib is 100 mg, taken twice daily.

As a continuous therapy, this treatment is taken until the CLL progresses or the side effects become intolerable. 

How Effective is Acalabrutinib for CLL?  

A 2023 ELEVATE-TN trial analysis examined the progression-free survival (PFS) rates of acalabrutinib combined with and without obinutuzumab for people with CLL as their first therapy. PFS refers to the percentage of patients in which the cancer has not progressed and/or are alive since the start of treatment. 

After 6 years from the start of treatment, the PFS rates were: 

• 78% of patients who took acalabrutinib + obinutuzumab
• 62% of patients who took acalabrutinib by itself

Side Effect Profile of Acalabrutinib for CLL

The percentage of people with CLL who experience mild-moderate versions of common side effects from acalabrutinib is shown below. 

For more information on these side effects, you can visit the Side Effects Management section of this guide. 

For more information on acalabrutinib, check out the source below.

• Calquence Prescribing Information

Financial Resources for Acalabrutinib

To locate financial resources for acalabrutinib, click here to visit the financial support section of the guide.